Celldex Receives a Buy from H.C. Wainwright

By Austin Angelo

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Celldex (NASDAQ: CLDX) today and set a price target of $6. The company’s shares opened today at $3.36.

According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -19.2% and a 23.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as X T L Biopharmaceuticals Ltd (ADR), Strata Skin Sciences Inc, and Spectrum Pharmaceuticals.

Currently, the analyst consensus on Celldex is Moderate Buy and the average price target is $7, representing a 108.3% upside.

In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $9 price target.

The company has a one year high of $5.13 and a one year low of $2.85. Currently, Celldex has an average volume of 1.82M.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CLDX in relation to earlier this year. Most recently, in September 2016, Tibor Keler, the Executive VP & CSO of CLDX bought 3,000 shares for a total of $9,960.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It’s immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA.